Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma

Hematology Journal

Volumn 1, Issue 6, 2000, Pages 367-373

  Micallef, Ivana N M ^a   Apostolidis, John ^a   Rohatiner, Ama Z S ^a   Wiggins, Claire ^a   Crawley, Charles R ^a   Foran, James M ^a   Leonhardt, Marcus ^a   Bradburn, Mike ^b   Okukenu, Emily ^a   Salam, Ashiq ^a   Matthews, Janet ^a   Cavenagh, Jamie D ^a   Gupta, Rajnish K ^a   Lister, T Andrew ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

G CSF; Lymphoma; Peripheral blood progenitor cell mobilisation

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; VIDARABINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD; BONE MARROW; DRUG EFFECT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKAPHERESIS; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; PATHOLOGY; REMISSION; STEM CELL MOBILIZATION;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; COMBINED MODALITY THERAPY; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKAPHERESIS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; REMISSION INDUCTION; VIDARABINE;

EID: 0034585610     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200061     Document Type: Article

References (37)

1. Gratwohl A, Passweg J, Baldomero H, Hermans J for the European group for blood and marrow transplantation (EBMT). Blood and marrow transplantation activity in Europe 1997. Bone Marrow Transplantation 19: 407, 1999.
2. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, McGrath KM, Morstyn G, Fox RM. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339: 640, 1992.
3. Beyer J, Schwella N, Zingsem J, Strohscheer I, Schwaner I, Oettle H, Serke S, Huhn D, Siegert W. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison. Journal of Clinical Oncology 13: 1328, 1995.
4. Schhmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HMS, Link H, Zander A, Barge A, Borkett K. Randomized trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347: 353, 1996.
5. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 89: 2233, 1997.
6. Bishop MR, Anderson JR, Jackson JD, Bierman PJ, Reed EC, Vose JM, Armitage JO, Warkentin PI, Kessinger A. High-dose therapy and peripheral blood progenitor cell transplantation: Effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood 83: 610, 1994.
7. Kröger N, Zeller W, Fehse N, Hassan HT, Krüger W, Gutensohn K, Lölliger C, Zander AR. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients. British Journal of Haematology 102: 1101, 1998.
8. Russell NH, McQuaker G, Stainer C, Byrne JL, Haynes AP. Stem cell mobilisation in lymphoproliferative diseases. Bone Marrow Transplantation 22: 935, 1998.
9. Zeller W, Gutensohn K, Stockschläder M, Dierlamm J, Kröger N, Koehne G, Hummel K, Kabisch H, Weh HJ, Kühnl P, Hossfeld DK, Zander AR. Increase of mobilised CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis. Bone Marrow Transplantation 17: 709, 1996.
10. Weaver CH, Birch R, Greco FA, Schwartzberg L, McAneny B, Moore M, Oviatt D, Redmond J, George C, Alberico T, Johnson P, Buckner CD. Mobilisation and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. British Journal of Haematology 100: 338: 1998.
11. Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K, Gooley T, Lynch M, Higano T, Klarnet J, Chauncey T, Storb R, Buckner CD. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhGCSF): an analysis of factors correlating with the tempo of engraftment after transplantation. British Journal of Haematology 87: 825, 1994.
12. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86: 3961, 1995.
13. + cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 91: 3148, 1998.
14. + cell content. Bone Marrow Transplantation 19: 1103, 1997.
15. Watts MJ, Sullivan AM, Leverett D, Peniket AJ, Perry AR, Williams CD, Devereux S, Goldstone AH, Linch DC. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilisation. Journal of Clinical Oncology 16: 1554, 1998.
16. Perry AR, Watts MJ, Peniket AJ, Goldstone AH, Linch DC. Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilised within 6 months of previous chemotherapy. Bone Marrow Transplantation 21: 1201, 1998.
17. Drake M, Ranaghan L, Morris TCM, Nolan L, Desai ZR, Irvine AE, Jordan A, Magill K, Price S. Analysis of the effect of prior therapy on progenitor cell yield: use of chemotherapy scoring system. British Journal of Haematology 98: 745, 1997.
18. Ketterer N, Salles G, Moullet I, Dumontet C, El Jaafari-Corbin A, Tremisi P, Thieblemont C, Durand B, Neidhardt-Berard EM, Samaha H, Rigal D, Coiffier B. Factors associated with successful mobilisation of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. British Journal of Haematology 103: 235, 1998.
19. Gandhi MK, Jestice K, Scott MA, Bloxham D, Bass G, Marcus RE. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplantation 23: 9, 1999.
20. Visani G, Lemoli RM, Tosi P, Martinelli G, Testoni N, Ricci P, Piccaluga PP, Pastano R, Leopardi G, Dizdari A, Motta MR, Rizzi S, Tura S. Fludarabine-containing regimens severely impair peripheral blood stem cell mobilisation and collection in acute myeloid leukaemia patients. British Journal of Haematology 105: 775, 1999.
21. Elliott C, Samson DM, Armitage S, Lyttelton MP, McGuigan D, Hargreaves R, Giles C, Abrahamson G, Abboudi Z, Brennan M, Kanfer EJ. When to harvest peripheral-blood stem cells after mobilisation therapy: Prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood. Journal of Clinical Oncology 14: 970, 1996.
22. Armitage S, Hargreaves R, Samson D, Brennan M, Kanfer E, Navarrete C. CD34 counts to predict the adequate collection of peripheral blood progenitor cells. Bone Marrow Transplantation 20: 587, 1997.
23. Auer RL, Holtom P, Smith H, Fegan CD, Milligan DW. Circulating CD34+ counts and apheresis planning. Hematological Oncology 16: 69, 1998.
24. + cell determination by flow cytometry. Journal of Hematotherapy 5: 211, 1996.
25. Harris NL, Jaffe S, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA. A revised European-American classification of lymphoid neoplasm: A proposal from the international lymphoma study group. Blood 84: 1361, 1994.
26. Freedman AS, Ritz J, Neuberg D, Anderson KC, Rabinowe SN, Mauch P, Takvorian T, Soiffer R, Blake K, Yeap B, Coral F, Nadler LM. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood 11: 2524, 1991.
27. Rohatiner AZS, Johnson PWM, Price CGA, Arnott SJ, Amess JAL, Norton AJ, Dorey E, Adams K, Whelan JS, Matthews J, MacCullum PK, Oza AM, Lister TA. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. Journal of Clinical Oncology 12: 1177, 1994.
28. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F, Chauvin F. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New England Journal of Medicine 333: 1540, 1995.
29. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, Gandola L, Tarella C, Pileri A, Ravagnani F, Valugussa P, Bonadonna G. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. New England Journal of Medicine 336: 1290, 1997.
30. Smith TJ, Hillner BE, Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Link H, Zander A, Yanovich S, Kitchin R, Erder MH. Economic analysis of a randomized clinical trial to compare filgrastim-mobilised peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. Journal of Clinical Oncology 15: 5, 1997.
31. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, Gooley T, Demirer T, Schiffman K, Weaver C, Clift R, Chauncey T, Klarnet K, Montgomery P, Petersdorf S, Weiden P, Witherspoon R, Buckner CD. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. Journal of Clinical Oncology 13: 2547, 1995.
32. Reiser M, Josting A, Draube A, Mapara MY, Scheid C, Chemnitz J, Tesch H, Wolf J, Diehl V, Söhngen D, Engert A. Successful peripheral blood stem cell mobilisation with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilisation. Bone Marrow Transplantation 23: 1223, 1999.
33. Watts MJ, Sullivan AM, Jamieson E, Pearce R, Fielding A, Devereux S, Goldstone AH, Linch DC. Progenitor-cell mobilisation after low-dose cyclophosphamide and granulocye colony stimulating factor: An analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. Journal of Clinical Oncology 15: 535, 1997.
34. Moskowitz CH, Stiff P, Gordon MS, McNeice I, Ho AD, Costa JJ, Broun ER, Bayer RA, Wyres M, Hill J, Jelaca-Maxwell K, Nichols CR, Brown SL, Nimer SD, Gabrilolve J. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilisation and transplantation in non-Hodgkin's lymphoma patients - results of a phase I/II trial. Blood 89: 3136, 1997.
35. Weaver A, Chang E, Wrigley E, de Wynter E, Woll PJ, Lind M, Jenkins B, Gill C, Wilkinson PM, Pettengell R, Radford JA, Collins CD, Dexter TM, Testa NG, Crowther D. Randomized comparison of progenitor-cell mobilisation using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. Journal of Clinical Oncology 16: 2601, 1998.
36. Shpall EJ, Wheeler CA, Turner SA, Yanovich S, Brown RA, Pecora AL, Shea TC, Mangan KF, Williams SF, LeMaistre CF, Long GD, Jones R, Davis MW, Murphy-Filkins R, Parker WRL, Glaspy JA. A randomized phase 3 study of peripheral blood progenitor cell mobilisation with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 93: 2491, 1999.
37. Shapiro F, Yao TJ, Moskowitz C, Reich L, Quest DL, Heimfoeld S, McNiece IK, Gabrilove J, Nimer S, Moore MA. Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilised CD34-positive progenitor cells. Clinical Cancer Research 3: 1571, 1997.